Navigation Links
DURECT Announces Proposed Public Offering of Common Stock
Date:11/7/2013

CUPERTINO, Calif., Nov. 7, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion and to meet working capital needs. All of the shares in the offering are to be sold by DURECT.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

Stifel is acting as sole book-running manager for the proposed offering and Janney Montgomery Scott is acting as co-manager.  

Felix Theeuwes, our Chairman and Chief Scientific Officer, has indicated an interest in purchasing shares of our common stock with an aggregate purchase price of up to approximately $1 million in this offering at the public offering price.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective.  A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov.  When available, copies of the preliminary prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.

NOTE: POSIDUR, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-Methylphenidate and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

 

 


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
2. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
3. DURECT Announces Changes to its Board of Directors
4. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
5. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
6. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
7. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
8. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
9. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
10. DURECT to Participate in Upcoming Healthcare Conferences
11. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 ... ... DACVIM, a board-certified veterinary oncologist, has agreed to serve as strategic adviser ... Dr. Tripp is founder of the Bridge Animal Referral Center (BARC) ...
(Date:9/19/2017)... Glen Cove, New York (PRWEB) , ... September 19, 2017 , ... ... that its dentist, Dr. Andrew Sami, was recently named one of the best dentists ... the leading lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the ...
(Date:9/19/2017)... ... 2017 , ... When it comes to household safety, there are few priorities ... to keep babies and toddlers safe, and there's no better time for companies to ... to Check Labels, Brands that sell all kinds of common consumer products should spend ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... Sarantos ... Fiction Fantasy Book This December , Sarantos is proud to be the 1st (and ... off every new song release. A new song, music video, book chapter and behind ...
Breaking Medicine News(10 mins):